Regulatory effect and mechanisms of carbon monoxide-releasing molecule II on hepatic energy metabolism in septic mice

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3301-3311

  Liang, Feng ^a   Cao, Jie ^a   Qin, Wei Ting ^a   Wang, Xu ^a   Qiu, Xue Feng ^a   Sun, Bing Wei ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Carbon monoxide; Energy metabolism; Liver; Regulation; Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; CARBON MONOXIDE RELEASING MOLECULE 2; FLUORODEOXYGLUCOSE F 18; GLUCOKINASE; LACTIC ACID; UNCLASSIFIED DRUG; CARBON MONOXIDE; GLUCOSE BLOOD LEVEL; ORGANOMETALLIC COMPOUND; TRICARBONYLDICHLORORUTHENIUM (II) DIMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECAL LIGATION; CONTROLLED STUDY; ENERGY METABOLISM; GLUCOSE METABOLISM; HISTOPATHOLOGY; LACTATE BLOOD LEVEL; LIGATION; LIVER FUNCTION; MALE; MITOCHONDRION SWELLING; MOUSE; NONHUMAN; PET SCANNER; PUNCTURE; SEPSIS; SURVIVAL RATE; ANIMAL; C57BL MOUSE; CECUM; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; MITOCHONDRION; POSITRON EMISSION TOMOGRAPHY; SURGERY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CARBON MONOXIDE; CECUM; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; SEPSIS;

EID: 84896975454     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3301     Document Type: Article

References (58)

1. Esteban E, Ferrer R, Alsina L, Artigas A. Immunomodula-tion in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge. Mediators Inflamm 2013; 2013: 507539[PMID: 24249974]
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554 [PMID: 12700374 DOI: 10.1056/NEJMoa022139]
3. Chioléro R, Revelly JP, Tappy L. Energy metabolism in sepsis and injury. Nutrition 1997; 13: 45S-51S [PMID: 9290109 DOI: 10.1016/S0899-9007(97)00205-0]
4. Kinney JM. Metabolic responses of the critically ill patient. Crit Care Clin 1995; 11: 569-585[PMID: 7552971]
5. Pereira CT, Herndon DN. The pharmacologic modulation of the hypermetabolic response to burns. Adv Surg 2005; 39: 245-261[PMID: 16250555 DOI: 10.1016/j.yasu.2005.05.005]
6. Holm C, Hörbrand F, Mayr M, von Donnersmarck GH, Mühlbauer W. Acute hyperglycaemia following thermal injury: friend or foe? Resuscitation 2004; 60: 71-77[PMID: 14987787 DOI: 10.1016/j.resuscitation.2003.08.003]
7. Pidcoke HF, Wade CE, Wolf SE. Insulin and the burned patient. Crit Care Med 2007; 35: S524-S530[PMID: 17713403]
8. Gore DC, Chinkes DL, Hart DW, Wolf SE, Herndon DN, Sanford AP. Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med 2002; 30: 2438-2442[PMID: 12441751 DOI: 10.1097/00003246-20021100 0-00006]
9. Pereira CT, Murphy KD, Herndon DN. Altering metabolism. J Burn Care Rehabil 2005; 26: 194-199[PMID: 15879740]
10. Wanek S, Wolf SE. Metabolic response to injury and role of anabolic hormones. Curr Opin Clin Nutr Metab Care 2007; 10: 272-277[PMID: 17414494 DOI: 10.1097/ MCO.0b013e3280f31b17]
11. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, De-sai M. Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 2001; 51: 540-544[PMID: 11535907 DOI: 10.1097/00005373-200109000-00021]
12. Gore DC, Herndon DN, Wolfe RR. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 2005; 59: 316-22; discussion 322-3 [PMID: 16294070 DOI: 10.1097/01.ta.0000180387.34057.5a]
13. Das UN. Insulin in sepsis and septic shock. J Assoc Physicians India 2003; 51: 695-700[PMID: 14621041]
14. Hirasawa H, Oda S, Nakamura M. Blood glucose control in patients with severe sepsis and septic shock. World J Gastro-enterol 2009; 15: 4132-4136[PMID: 19725146 DOI: 10.3748/ wjg.15.4132]
15. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297[PMID: 19318384 DOI: 10.1056/NEJMoa0810625]
16. Sun B, Sun H, Liu C, Shen J, Chen Z, Chen X. Role of CO-releasing molecules liberated CO in attenuating leukocytes sequestration and inflammatory responses in the lung of thermally injured mice. J Surg Res 2007; 139: 128-135[PMID: 17292406 DOI: 10.1016/j.jss.2006.08.032]
17. Sun BW, Chen ZY, Chen X, Liu C. Attenuation of leukocytes sequestration by carbon monoxide-releasing molecules: liberated carbon monoxide in the liver of thermally injured mice. J Burn Care Res 2007; 28: 173-181[PMID: 17211222 DOI: 10.1097/BCR.0b013E31802CA491]
18. Liu DM, Sun BW, Sun ZW, Jin Q, Sun Y, Chen X. Suppression of inflammatory cytokine production and oxida-tive stress by CO-releasing molecules-liberated CO in the small intestine of thermally-injured mice. Acta Pharmacol Sin 2008; 29: 838-846[PMID: 18565282 DOI: 10.1111/ j.1745-7254.2008.00816.x]
19. Sun B, Sun Z, Jin Q, Chen X. CO-releasing molecules (CORM-2)-liberated CO attenuates leukocytes infiltration in the renal tissue of thermally injured mice. Int J Biol Sci 2008; 4: 176-183[PMID: 18566696]
20. Wang X, Cao J, Sun BW, Liu DD, Liang F, Gao L. Exogenous carbon monoxide attenuates inflammatory responses in the small intestine of septic mice. World J Gastroenterol 2012; 18: 5719-5728[PMID: 23155312 DOI: 10.3748/wjg.v18.i40.5719]
21. Stein AB, Guo Y, Tan W, Wu WJ, Zhu X, Li Q, Luo C, Dawn B, Johnson TR, Motterlini R, Bolli R. Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol 2005; 38: 127-134[PMID: 15623429 DOI: 10.1016/j.yjmcc.2004.10.006]
22. Sun BW, Sun Y, Sun ZW, Chen X. CO liberated from CORM-2 modulates the inflammatory response in the liver of thermally injured mice. World J Gastroenterol 2008; 14: 547-553[PMID: 18203286 DOI: 10.3748/wjg.13.6127]
23. Langah R, Spicer K, Chang R, Rosol M. Inhibition of Physiologic Myocardial FDG Uptake in Normal Rodents: Comparison of Four Pre-Scan Preparation Protocols. AMI 2012; 2: 21-30[DOI: 10.4236/ami.2012.23004]
24. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36: 1301-1306[PMID: 7790960]
25. Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, Sato N, Konishi J. Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med 2002; 43: 658-663[PMID: 11994531]
26. Austin J, Aprille JR. Carboxyatractyloside-insensitive influx and efflux of adenine nucleotides in rat liver mitochondria. J Biol Chem 1984; 259: 154-160[PMID: 6706925]
27. Sriskandan S. Severe peripartum sepsis. J R Coll Physicians Edinb 2011; 41: 339-346[PMID: 22184573]
28. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40: 754-761[PMID: 21963582 DOI: 10.1097/ CCM.0b013e318232db65]
29. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 2003; 31: 2316-2323[PMID: 14501962 DOI: 10.1097/01.CCM.0000085178.80226.0B]
30. Felbinger TW, Suchner U, Goetz AE. Treating patients with severe sepsis. N Engl J Med 1999; 341: 56-57 [PMID: 10391763 DOI: 10.1056/NEJM199907013410113]
31. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL, Platt R. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-240[PMID: 9218672 DOI: 10.1001/jama. 1997.03550030074038]
32. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-S116[PMID: 11445744]
33. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170: 1435-1444[PMID: 17456750 DOI: 10.2353/aj-path.2007.060872]
34. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-787[PMID: 18802444 DOI: 10.1038/nri2402]
35. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009; 37: 291-304[PMID: 19050640 DOI: 10.1097/CCM.0b013e31819267fb]
36. Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: propranolol. Crit Care Med 2007; 35: S616-S620[PMID: 17713418]
37. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004; 30: 748-756[PMID: 14991101 DOI: 10.1007/s00134-004-2167-y]
38. Van Cromphaut SJ, Vanhorebeek I, Van den Berghe G. Glucose metabolism and insulin resistance in sepsis. Curr Pharm Des 2008; 14: 1887-1899[PMID: 18691100 DOI: 10.2174/13816 1208784980563]
39. Taylor JH, Beilman GJ. Hyperglycemia in the intensive care unit: no longer just a marker of illness severity. Surg Infect (Larchmt) 2005; 6: 233-245[PMID: 16128630 DOI: 10.1089/ sur.2005.6.233]
40. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM. Admission hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 2005; 59: 80-83[PMID: 16096543 DOI: 10.1097/01.TA.0000171452.96585.84]
41. Turina M, Fry DE, Polk HC. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med 2005; 33: 1624-1633 [PMID: 16003073 DOI: 10.1097/01.CCM.0000170106.61978.D8]
42. Ali NA, O'Brien JM, Dungan K, Phillips G, Marsh CB, Lem-eshow S, Connors AF, Preiser JC. Glucose variability and mortality in patients with sepsis. Crit Care Med 2008; 36: 2316-2321[PMID: 18596625]
43. Waeschle RM, Moerer O, Hilgers R, Herrmann P, Neumann P, Quintel M. The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability. Crit Care 2008; 12: R129[PMID: 18939991]
44. Levy B. Lactate and shock state: the metabolic view. Curr Opin Crit Care 2006; 12: 315-321[PMID: 16810041 DOI: 10.1097/01.ccx.0000235208.77450.15]
45. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauw-ers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367[PMID: 11794168 DOI: 10.1056/NEJMoa011300]
46. Van den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouck-aert B, Bruyninckx F, Bouillon R, Schetz M. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006; 55: 3151-3159[PMID: 17065355 DOI: 10.2337/db06-0855]
47. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ra-galler M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natan-son C, Loeffer M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139[PMID: 18184958 DOI: 10.1056/NEJMoa070716]
48. Hintze KJ, Theil EC. Cellular regulation and molecular interactions of the ferritins. Cell Mol Life Sci 2006; 63: 591-600[PMID: 16465450 DOI: 10.1007/s00018-005-5285-y]
49. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Ro-della LF, Aronow WS, Ikehara S, Abraham NG. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57: 1526-1535[PMID: 18375438 DOI: 10.2337/db07-1764]
50. Motterlini R, Mann BE, Johnson TR, Clark JE, Foresti R, Green CJ. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Curr Pharm Des 2003; 9: 2525-2539[PMID: 14529551 DOI: 10.2174/1381612033453785]
51. Maruyama K, Morishita E, Yuno T, Sekiya A, Asakura H, Ohtake S, Yachie A. Carbon monoxide (CO)-releasing molecule-derived CO regulates tissue factor and plasminogen activator inhibitor type 1 in human endothelial cells. Thromb Res 2012; 130: e188-e193[PMID: 22819264 DOI: 10.1016/ j.thromres.2012.07.002]
52. Tsoyi K, Ha YM, Kim YM, Lee YS, Kim HJ, Kim HJ, Seo HG, Lee JH, Chang KC. Activation of PPAR-gamma by carbon monoxide from CORM-2 leads to the inhibition of iNOS but not COX-2 expression in LPS-stimulated macrophages. In-fammation 2009; 32: 364-371[PMID: 19705266 DOI: 10.1007/ s10753-009-9144-0]
53. Tsoyi K, Lee TY, Lee YS, Kim HJ, Seo HG, Lee JH, Chang KC. Heme-oxygenase-1 induction and carbon monoxide-releasing molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box 1 release in vitro and improve survival of mice in LPS- and cecal ligation and puncture-induced sepsis model in vivo. Mol Pharmacol 2009; 76: 173-182[PMID: 19366789 DOI: 10.1124/mol.109.055137]
54. Mizuguchi S, Stephen J, Bihari R, Markovic N, Suehiro S, Capretta A, Potter RF, Cepinskas G. CORM-3-derived CO modulates polymorphonuclear leukocyte migration across the vascular endothelium by reducing levels of cell surface-bound elastase. Am J Physiol Heart Circ Physiol 2009; 297: H920-H929[PMID: 19561312 DOI: 10.1152/ajp-heart.00305.2009]
55. Cepinskas G, Katada K, Bihari A, Potter RF. Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammations in the liver of septic mice. Am J Physiol Gastrointest Liver Physiol 2008; 294: G184-G191[PMID: 17991708]
56. Barkhausen T, Probst C, Hildebrand F, Pape HC, Krettek C, van Griensven M. Insulin therapy induces changes in the inflammatory response in a murine 2-hit model. Injury 2009; 40: 806-814[PMID: 19167710 DOI: 10.1016/ j.injury.2008.07.018]
57. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238: E69-E82[PMID: 6965568]
58. Mittra E, Quon A. Positron emission tomography/computed tomography: the current technology and applications. Radiol Clin North Am 2009; 47: 147-160[PMID: 19195540 DOI: 10.1016/j.rcl.2008.10.005]